

# **Drug Delivery in Cancer**

## **Part I: Technologies & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**September 2020**

**A Jain PharmaBiotech Report**

## A U T H O R ' S   B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 484 publications include 32 books (6 as editor+ 26 as author) and 50 special reports, which have covered biotechnology and biopharmaceuticals topics; e.g., molecular diagnostics, biomarkers, proteomics, cell therapy, gene therapy, drug delivery nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2020, in preparation), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Drug-induced Neurological Disorders" (4th ed, Springer 2020) "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Drug Delivery to the Central Nervous System" (Humana/Springer, 2010) and "Applied Neurogenomics" (Springer 2015). Essentials of Personalized Medicine (in Russian, with Prof. K. Sharipov as co-author), 2019 was published by LITERRA Publishing House, Moscow.

## A B O U T   T H I S   R E P O R T

The original report on Drug Delivery in Cancer by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was published at Jain PharmaBiotech in 2003 and has been constantly updated and rewritten since then.

**September 2020 (first edition published in 2000)**  
**Copyright © 2020 by**

**Jain PharmaBiotech**  
Bläsiring 7  
CH-4057 Basel  
Switzerland

**Tel & Fax:** +4161-6924461  
**Email:** info@pharmabiotech.ch  
**Web site:** <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# T A B L E   O F   C O N T E N T S

<b>0. Executive Summary .....</b>	<b>22</b>
<b>1. Introduction to cancer therapy .....</b>	<b>24</b>
<b>Molecular biology of cancer .....</b>	<b>24</b>
Cell cycle and cancer.....	24
<i>Apoptosis in cancer .....</i>	25
<i>Autophagy .....</i>	25
<i>Cell division and mitotic spindles.....</i>	26
<i>PD-1 Pathway.....</i>	26
<i>DNA damage, repair and cancer.....</i>	27
<i>Mechanism of DNA damage in Fanconi anemia leading to leukemia .....</i>	27
Cancer metabolism and energy status in relation to growth.....	27
<i>Amino acids and cancer .....</i>	27
<i>AMP-activated protein kinase.....</i>	28
<i>Cancer therapeutics that target metabolism. ....</i>	28
Cancer cell dormancy .....	29
<i>Dormancy and relapse in cancer .....</i>	29
<i>Activating dormant cancer cells for enhancing chemotherapy .....</i>	29
Chromosomes and cancer .....	30
<i>Aneuploidy.....</i>	30
<i>Chromosomal instability.....</i>	30
<i>Extrachromosomal DNA and cancer .....</i>	31
<i>Telomeres and cancer.....</i>	31
Genes and cancer .....	32
<i>Accumulation of random mutations .....</i>	32
<i>Oncogenes.....</i>	32
<i>Role of Bub 1 gene in cell division .....</i>	32
<i>Tumor Suppressor Genes .....</i>	33
Hallmarks of cancer.....	34
Hypoxia of cancer cells .....	34
Invasion and metastases .....	35
<i>Tumor suppressor genes and metastases.....</i>	37
Methylation and cancer.....	37
Nitric oxide and cancer .....	37
<i>Inflammation, NO and colon cancer.....</i>	38
<i>NO and tumor hypoxia.....</i>	39
<i>NO and p53 mutations.....</i>	39
<i>NO and matrix metalloproteinase .....</i>	40
<i>Role of NO in angiogenesis in cancer .....</i>	40
Oxidative stress and cancer.....	41
Role of platelet-derived growth factor in proliferation of cancer.....	42
RNA and cancer .....	42
<i>Anticancer treatments based on RNA regulation of genes .....</i>	42
<i>Role of microRNAs in cancer .....</i>	42
Stem cells and cancer.....	43
Self-sufficiency of tumor proliferation .....	44
Therapeutic implications of apoptosis in cancer.....	44
Tumor angiogenesis .....	46
<i>Pathomechanism of angiogenesis.....</i>	46
<i>Role of VEGF in angiogenesis.....</i>	48
<i>Matrix stiffness-mediated angiogenesis in tumors .....</i>	48
Tumor-associated macrophages in cancer .....	48
<b>Cancer biomarkers.....</b>	<b>49</b>
Molecular imaging of cancer .....	49
<b>Cancer genomics.....</b>	<b>49</b>
Gene expression profiling in cancer .....	49
<b>Cancer proteomics .....</b>	<b>50</b>
<b>Limitations of genomics and proteomics for understanding cancer .....</b>	<b>50</b>
<b>Cancer microenvironment.....</b>	<b>51</b>
<b>Epidemiology of cancer.....</b>	<b>51</b>
<b>Current management of cancer.....</b>	<b>52</b>
Anticancer drugs.....	52
<i>Limitations of cancer chemotherapy .....</i>	53
Biological therapies for cancer .....	53
Radiotherapy .....	53
<i>Brachytherapy .....</i>	53
Ideal anticancer agent .....	53
Surgery .....	54

<b>Basics of drug delivery in cancer .....</b>	<b>54</b>
Role of mechanical forces in tumor growth and delivery of therapy .....	54
<b>Methods of assessing drug delivery in cancer.....</b>	<b>55</b>
Positron emission tomography (PET) .....	55
<b>Historical landmarks in cancer drug delivery .....</b>	<b>55</b>
<b>2. Innovative treatments for cancer .....</b>	<b>58</b>
<b>Introduction .....</b>	<b>58</b>
<b>Selective estrogen receptor modulators .....</b>	<b>59</b>
<b>Antiangiogenic strategies for cancer .....</b>	<b>59</b>
Development of antiangiogenic therapies .....	60
Classification of antiangiogenic agents .....	60
Examples of antiangiogenic agents.....	62
<i>ACE-041 .....</i>	62
<i>Angiopoietin-2 as a target.....</i>	62
<i>Chemotherapy at lower than maximum tolerated dose .....</i>	62
<i>Galectin-3 as a target for inhibiting angiogenesis .....</i>	62
<i>Inhibitors of endothelial proliferation .....</i>	63
<i>Inducers of apoptosis of endothelial cells of tumor vessels .....</i>	63
<i>Lodamin .....</i>	63
<i>Matrix metalloproteinase inhibitors.....</i>	64
<i>Monoclonal antibodies with vasculostatic properties.....</i>	64
<i>PPAR<math>\alpha</math> agonists.....</i>	65
<i>Rapalogues as antiangiogenic agents.....</i>	66
<i>VEGF Trap.....</i>	66
Agents that decrease the permeability of tumor blood vessels .....	66
Antiangiogenic agents in clinical trials.....	67
Antiangiogenic therapy resistance .....	67
Combination of antiangiogenic with cytotoxic therapy .....	67
Antiangiogenic therapy for hematological malignancies.....	68
<b>Bacterial anticancer agents .....</b>	<b>69</b>
Tumor-targeted bacteria .....	69
<i>Bacterial protein for targeted delivery of liposomal cancer drugs.....</i>	70
<i>Bacterial carriers for targeted drug delivery to brain tumors.....</i>	70
<i>Genetically modified bacteria as anticancer agents.....</i>	70
<i>Live bacteria for delivering radioactive anticancer agents .....</i>	71
<i>Synchronized cycles of bacterial lysis with delivery of chemotherapy .....</i>	71
<i>Genetically altered strains of Salmonella as anticancer drug vectors .....</i>	72
Inactivated but metabolically active bacteria .....	72
Bacterial toxins targeted to tumors .....	73
<i>Immunotoxins .....</i>	73
<i>Escherichia Coli toxins .....</i>	73
<i>Engineered anthrax toxin .....</i>	73
<i>Recombinant fusion toxins .....</i>	74
Type III secretion systems.....	75
Induction of apoptosis in cancer by bacterial proteins .....	76
Induction of immune response by bacteriolytic therapy.....	76
<b>Epigenetic targets for anticancer therapy .....</b>	<b>76</b>
<b>Innovations in cell therapy for cancer .....</b>	<b>77</b>
Stem cell transplantation for cancer .....	77
Cancer drug/gene delivery by mesenchymal stem cells.....	78
<b>Cancer immunotherapy.....</b>	<b>78</b>
Cytokines.....	79
Epigenetic modulators and cancer immunotherapies.....	79
STING activation and antitumor immunity .....	81
Cancer vaccines.....	81
<i>5T4 as a target for cancer immunotherapy .....</i>	82
<i>Adoptive cell therapy.....</i>	83
<i>Antigen-specific cancer vaccines .....</i>	85
<i>Carcinoembryonic antigen-based vaccines.....</i>	86
<i>Carbohydrate-based cancer vaccines .....</i>	86
<i>Dendritic cells for cancer vaccination .....</i>	86
<i>Hybrid cell vaccination .....</i>	88
<i>SMART vaccines.....</i>	89
<i>Salmonella-based oral vaccine delivery.....</i>	89
<i>Tumor cell vaccines .....</i>	89
<i>Vaccines that simultaneously target different cancer antigens .....</i>	90
<i>Vaccines based on multiple tumor-associated peptides .....</i>	91
<i>Vaccine for cancer based on antimalaria protein.....</i>	91
Cancer Vaccine Consortium .....	91
Chemoimmunotherapy .....	91

Concluding remarks about cancer vaccines.....	92
Targeted delivery of peptides to tumor-associated macrophages.....	92
Targeting cancer stem cells.....	92
<b>Monoclonal antibodies .....</b>	<b>93</b>
Murine MAbs .....	93
Humanized MAbs .....	93
Actions and uses of MAbs in cancer .....	94
<i>Anti PD-1 and anti PD-L1 MAbs</i> .....	95
Targeted antibody-based cancer therapy .....	95
<i>Antibody-cytokine fusion proteins</i> .....	95
<i>Antibody ARGX-115 for targeting immunosuppressive effect of Tregs</i> .....	95
<i>Antibody J591 for targeted delivery of anticancer therapy</i> .....	95
<i>Anti-Thomsen-Friedenreich antigen MAb</i> .....	96
<i>Combining MAbs with anti-CD55 antibody</i> .....	96
<i>MAbs targeted to alpha fetoprotein receptor</i> .....	96
<i>MAbs that target angiogenesis</i> .....	97
<i>MAbs as phagocyte checkpoint inhibitors</i> .....	97
MAbs for immune activation .....	97
Delivery of cancer therapy with MAbs .....	98
Antibody-directed enzyme prodrug therapy .....	99
Chemically programmed antibodies .....	99
Combining diagnostics with therapeutics based on MAbs .....	100
Radiolabeled antibodies for detection and targeted therapy of cancer .....	100
Other innovations for administration of antibodies.....	102
<i>Bispecific antibodies</i> .....	103
<i>Trifunctional antibodies</i> .....	103
<i>Tetravalent bispecific antibodies</i> .....	104
<i>Immunotoxins</i> .....	104
<i>Immunoliposomes</i> .....	104
<i>Combined use of MAbs and cytokines</i> .....	105
<i>huHMFG1-huDnase I</i> .....	105
<i>MAbs that selectively target cancer</i> .....	105
G-MAB technology .....	106
NanoMAbs for targeted anticancer drug delivery .....	106
Advantages and limitations of MAbs for cancer therapy.....	107
Antibody-drug conjugates .....	108
<i>Kadcyla</i> .....	109
<i>Adcetris</i> .....	110
Antibody-enzyme conjugates.....	110
Current and future trends in antibody-based cancer drugs .....	110
<b>Innovative methods of radiation delivery .....</b>	<b>110</b>
Image-guided ultrasound technology for delivery of radiation .....	110
Respiratory gating technology for radiation therapy .....	111
Positron therapy .....	111
Boron neutron capture therapy .....	112
<i>Application of drug delivery systems to BNCP</i> .....	112
<i>Use of nanotechnology to enhance BNCT</i> .....	113
<b>Ion channels and transporters in cancer.....</b>	<b>113</b>
<b>Irreversible electroporation.....</b>	<b>114</b>
<b>Methods to overcome multidrug resistance (MDR) .....</b>	<b>114</b>
Mechanism of MDR.....	115
<i>MDR-associated protein gene</i> .....	115
<i>P-glycoprotein-mediated MDR</i> .....	115
Strategies for overcoming MDR.....	115
<i>Blocking the action of P-glycoprotein</i> .....	116
<i>Combination of targeted drugs with different specificities</i> .....	116
<i>Enzyme Catalyzed Therapeutic Activation</i> .....	116
<i>Inhibition of DNA repair</i> .....	117
<i>Iron chelators that overcomes resistance to chemotherapeutics</i> .....	117
<i>Liposome formulation of anticancer drugs</i> .....	117
<i>Modification of the chemical structure of the anticancer drug</i> .....	118
<i>Managing resistance to antiapoptotic action of anticancer agents</i> .....	118
<i>Modulation of SPARC expression</i> .....	118
<i>Nanoparticles for producing reactive oxygen species in mitochondria</i> .....	118
<i>Nitric oxide inducers</i> .....	119
<i>Proton pump inhibitors</i> .....	119
<i>Repression of Prohibitin1 in drug-resistant cancer cells</i> .....	119
<i>Targeting proteins associated with cancer stem cells</i> .....	120
<b>Targeted cancer therapies .....</b>	<b>120</b>
Targeting cellular pathways.....	120
Targeting antigens in virus-associated cancer .....	121

Targeting the IGF-I receptor.....	121
Targeting Mcl-1 protein.....	121
Targeting mitochondrial membranes .....	122
Targeting tumor lymphatics.....	123
<i>LyP-1 for targeting tumor lymphatics.</i> .....	123
Targeting tyrosine kinase receptors.....	123
<i>Inhibitors of bcr-abl tyrosine kinase .....</i>	124
<i>Inhibition of multiple tyrosine kinases.....</i>	124
<i>Inhibitors of ErBB tyrosine kinase.....</i>	124
Targeting the Hedgehog signaling pathway .....	125
Targeting caspase-8.....	125
Targeting metallodrugs to tumor cells.....	126
Targeting oncogenes .....	126
Targeting miRNA for cancer therapeutics .....	127
Targeting the transferrin receptor-mediated endocytosis pathway.....	127
Targeted anticancer therapies based on the Rad51 promoter.....	127
Targeting cancer stem cells.....	127
Targeting glycolytic pathway in cancer.....	129
Targeting glycoproteins .....	129
<i>Tagging cancer with modified sugars.....</i>	130
<i>Anticancer agents based on glycobiology .....</i>	130
<i>Targeting cell surface glycoproteins.....</i>	130
<i>Biofusion for targeted cancer therapy.....</i>	130
Targeting knottin peptides .....	131
Tarveda's Pentarin platform for targeted drug conjugates .....	131
<b>Enhancing the effects of radiation and chemotherapy .....</b>	<b>132</b>
Sensitizing and enhancing agents for chemotherapy.....	132
<i>CoFactor to enhance the efficacy of chemotherapy.....</i>	132
<i>Enzyme-enhanced chemotherapy.....</i>	132
<i>Resveratrol and quercetin for cardioprotection against chemotherapy.....</i>	133
<i>Tesmilifene for chemosensitization .....</i>	133
Sensitizing agents for radiotherapy .....	133
<i>IPdR.....</i>	133
<i>Ultrasound for enhancing response to radiation .....</i>	134
Manipulation of tumor oxygenation .....	134
<i>Hypoxia-based methods to enhance chemotherapy and radiotherapy .....</i>	134
<i>Hyperbaric oxygen and radiation.....</i>	135
<i>HIF-1 antagonists to enhance radiotherapy .....</i>	135
<i>Nonsteroidal antiinflammatory drugs enhance tumor radiosensitivity .....</i>	136
<i>ONCONASE as radiosensitivity enhancer .....</i>	136
Hyperthermia and chemotherapy/radiation therapy.....	136
<i>Techniques for hyperthermia .....</i>	136
<i>Trimodality therapy: radiation, chemotherapy, and hyperthermia .....</i>	137
Photodynamic therapy .....	137
<i>Photochemical internalization .....</i>	140
Thermal combination with focused ultrasound for drug delivery to tumors.....	140
<b>Novel anticancer agents .....</b>	<b>140</b>
Anti-EphA2 antibodies .....	140
Antioxidants .....	141
Brostallicin .....	141
Agents disrupting folate metabolism.....	141
<i>Pemetrexed.....</i>	141
Cell cycle inhibitors .....	142
Cytotoxic ribonucleases .....	142
DNA hypomethylating agents .....	143
Histone-based cancer therapy .....	143
<i>Histone deacetylase inhibitors .....</i>	143
<i>Modulation of p300/CBP histone acetyltransferase activity .....</i>	144
<i>Simulation of endogenous histone for anticancer therapy .....</i>	144
HSP90 inhibitors .....	145
Ion channel blockers .....	145
<i>IOT-101.....</i>	145
<i>Endovion .....</i>	146
LPAAT-β inhibitors.....	146
Modulation of pyruvate kinase M2 .....	146
Modulators of protein ubiquitination .....	146
P13-kinase inhibitors.....	147
PARP inhibitors .....	147
<i>Targeted destruction of BRCA2 deficient tumors by PARP inhibitors .....</i>	147
<i>Companies developing and commercializing PARP inhibitors .....</i>	148
Prodrugs.....	149

<i>Enzyme-activated prodrugs</i> .....	149
<i>Ascorbic acid as a prodrug for cancer</i> .....	149
<i>Polarix</i> .....	149
<i>Procaspase-3 activation</i> .....	149
<i>Protein kinase G activation</i> .....	150
<i>Proteasome inhibitors</i> .....	150
<i>Recombinant human insulin-like growth factor binding protein-3</i> .....	150
<i>Second generation nucleosides</i> .....	151
<i>Targeting cancer metabolism</i> .....	151
<i>Targeting topoisomerase IB</i> .....	152
<i>Telomerase inhibitors</i> .....	153
<i>Therapeutic strategies based on the P53 pathway</i> .....	153
<i>Therapeutic strategies based on molecular mechanisms</i> .....	154
<i>Checkpoint activation as a strategy against cancer</i> .....	154
<i>Deletion-specific targeting for cancer therapy</i> .....	154
<i>In vivo models for molecularly anticancer drugs</i> .....	155
<i>Repair-blocking drugs for enhancing effect of chemotherapy</i> .....	155
<i>Tumor targeting fields</i> .....	155
<i>Targeting mTOR signaling defects</i> .....	156
<i>Combining novel anticancer approaches</i> .....	156
<b>Personalized therapy of cancer</b> .....	<b>157</b>
<i>Challenges of cancer classification</i> .....	159
<i>Design of future cancer therapies</i> .....	159
<i>Personalized drug development in oncology</i> .....	160
<i>Role of molecular imaging</i> .....	160
<i>Role of molecular imaging in targeted cancer therapy</i> .....	161
<i>Screening for personalized anticancer drugs</i> .....	162
<i>Targeting pathways for personalized cancer therapy</i> .....	162
<b>3. Drug delivery systems for cancer</b> .....	<b>164</b>
<b>Introduction</b> .....	<b>164</b>
<b>Routes of drug delivery in cancer</b> .....	<b>164</b>
<i>Intravenous delivery systems for cancer therapy</i> .....	165
<i>Intravenous versus oral ascorbate for treatment of cancer</i> .....	166
<i>Subcutaneous injection of anticancer agents</i> .....	166
<i>Oral delivery of anticancer agents</i> .....	166
<i>5-FU combined with eniluracil</i> .....	168
<i>Cyclin D-dependent CDK4 and CDK6 inhibitors</i> .....	168
<i>High dose administration of calcitriol</i> .....	168
<i>Oral fluoropyrimidines</i> .....	169
<i>Oral gefitinib vs intravenous docetaxel</i> .....	169
<i>Oral paclitaxel</i> .....	170
<i>Oral satraplatin</i> .....	170
<i>Oral UFT</i> .....	170
<i>Oral PXD101</i> .....	171
<i>Transdermal drug delivery</i> .....	171
<i>Delivery of the photosensitizer drug δ-amino levulinic acid</i> .....	171
<i>Nanoemulsion-based delivery of caffeine for skin cancer</i> .....	171
<i>Transdermal delivery of methotrexate</i> .....	172
<i>Transdermal nitroglycerine for prostate cancer</i> .....	172
<i>Transdermal delivery of peptide cancer vaccines</i> .....	172
<i>Intradermal delivery of cancer vaccines by adenoviral vectors</i> .....	172
<i>Pulmonary delivery of anticancer agents</i> .....	173
<i>Regional intra-arterial delivery of chemotherapy</i> .....	173
<i>Gas embolotherapy of tumors</i> .....	174
<i>Drug delivery to lymph nodes</i> .....	174
<i>Intraperitoneal macrophages as drug delivery vehicle</i> .....	175
<i>Challenges of cancer drug delivery</i> .....	175
<i>Tumor blood vessel pore barrier to drug delivery</i> .....	175
<i>Improvement of drug transport in tumors</i> .....	175
<i>Delivery of anticancer drugs to nuclear targets</i> .....	176
<b>Innovative formulations for drug delivery in cancer</b> .....	<b>177</b>
<i>Cancer targeting with polymeric drugs</i> .....	177
<i>Linking anticancer drugs to polyglutamate</i> .....	178
<i>Improving delivery of protein-polymer anticancer drugs</i> .....	178
<i>Aldoxorubicin</i> .....	179
<i>Linker activated anticancer drug delivery</i> .....	179
<i>Macromolecules as delivery systems for taxanes</i> .....	180
<i>Polyamine conjugates as anticancer agents</i> .....	180
<i>Bacterial vectors as drug delivery systems for anticancer drugs</i> .....	180
<i>Microparticles as therapeutic delivery systems in cancer</i> .....	181

<i>Subcutaneous injection of microspheres carrying anticancer drugs</i> .....	181
<i>Intravascular delivery systems using microparticles</i> .....	182
<i>Tumor embolization with drug-eluting beads</i> .....	182
<i>Tumor embolization with radioactive microparticles</i> .....	182
<i>Microparticles heated by magnetic field</i> .....	183
<i>Magnetic targeted microparticle technology</i> .....	183
<i>Release of drugs from biSphere by ultrasound</i> .....	183
<i>Release of drugs from micelles by ultrasound</i> .....	184
<i>Release of drugs from microcapsules by laser</i> .....	184
<i>Chemoembolization</i> .....	184
<i>Anticancer drugs bound to carbon particles</i> .....	185
<i>Anticancer drugs bound to protein microspheres</i> .....	185
<i>Nanoerythrocytes</i> .....	185
<b>Nanobiotechnology-based drug delivery for cancer</b> .....	<b>185</b>
Nanoparticle formulations for drug delivery in cancer .....	187
<i>Anticancer drug particles incorporated in liposomes</i> .....	187
<i>Doxorubicin nanocarriers</i> .....	188
<i>Encapsulating drugs in hydrogel nanoparticles</i> .....	189
<i>Exosomes</i> .....	190
<i>Folate-linked nanoparticles</i> .....	190
<i>Lipid based nanocarriers</i> .....	190
<i>Micelles for drug delivery in cancer</i> .....	191
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i> .....	192
<i>Nanobombs for cancer</i> .....	193
<i>Nanodiamonds for local delivery of chemotherapy at site of cancer</i> .....	193
<i>Nanoparticle formulation for enhancing anticancer efficacy of cisplatin</i> .....	194
<i>Nanoparticle formulations of paclitaxel</i> .....	194
<i>Nanoparticles containing albumin and antisense oligonucleotides</i> .....	194
<i>Nanotechnology-based non-invasive refilling of drug delivery depots</i> .....	195
<i>Non-aggregating nanoparticles</i> .....	195
<i>Pegylated nanoliposomal formulation</i> .....	195
<i>Perfluorocarbon nanoparticles</i> .....	196
<i>PFTBA@Alb nanoparticles as enhancers of anti-PD-L1 immunotherapy</i> .....	196
<i>Polymer nanoparticles for drug delivery</i> .....	196
<i>Protein nanocages for penetration of airway mucous and tumors</i> .....	196
<i>Protosphere nanoparticle technology</i> .....	197
Nanoparticles-based targeted delivery of therapeutics for cancer .....	197
<i>Antiangiogenic therapy using nanoparticles</i> .....	198
<i>Carbon magnetic nanoparticles for targeted drug delivery in cancer</i> .....	199
<i>Carbon nanotubes for targeted drug delivery to cancer cells</i> .....	199
<i>CRLX101 for targeted anticancer drug delivery</i> .....	200
<i>DNA aptamer-micelle for targeted drug delivery in cancer</i> .....	200
<i>Fullerenes for enhancing tumor targeting by antibodies</i> .....	200
<i>Gold nanoparticles for targeted drug delivery in cancer</i> .....	201
<i>Hepatic artery infusion of LDL-DHA nanoparticles for liver cancer</i> .....	202
<i>Iron oxide magnetic nanoparticle formulation for drug delivery</i> .....	202
<i>Laser irradiation for targeted release of drugs from nanocontainers</i> .....	202
<i>Lipoprotein nanoparticles targeted to cancer-associated receptors</i> .....	203
<i>Magnetic nanoparticles for remote-controlled drug delivery to tumors</i> .....	203
<i>Monitoring of targeted delivery by nanoparticle-peptide conjugates</i> .....	204
<i>Nanobees for targeted delivery of cytolytic peptide melittin</i> .....	204
<i>Nanocell for targeted drug delivery to tumor</i> .....	204
<i>Nanodroplets for site-specific cancer treatment</i> .....	205
<i>Nanogel-based stealth cancer vaccine targeting macrophages</i> .....	205
<i>Nanoparticle-mediated targeted delivery of peptides into tumors</i> .....	206
<i>Nanoparticle-mediated targeting of MAPK signaling pathway</i> .....	206
<i>Nanoparticles for targeted delivery of concurrent chemoradiation</i> .....	207
<i>Nanostructured hyaluronic acid for targeted drug delivery in cancer</i> .....	207
<i>Nanoparticles as antibody-drug conjugates</i> .....	207
<i>Nanoparticle-coated peptides for tumor targeting</i> .....	208
<i>Nanoparticle-mediated delivery of multiple anticancer agents</i> .....	208
<i>Nanovesicle-mediated drug delivery in cancer</i> .....	208
<i>Polymer nanoparticles for targeted drug delivery in cancer</i> .....	208
<i>Polymersomes for targeted anticancer drug delivery</i> .....	209
<i>Quinic acid-nanoparticle conjugates</i> .....	209
<i>Targeted drug delivery with nanoparticle-aptamer bioconjugates</i> .....	210
<i>Targeted nanoparticles delivery of cisplatin to mitochondrial genome</i> .....	211
<i>Time-delayed, dual-drug nanoparticle delivery system for cancer</i> .....	211
Dendrimers for anticancer drug delivery .....	212
<i>Application of dendrimers in boron neutron capture therapy</i> .....	213
<i>Application of dendrimers in photodynamic therapy</i> .....	213

<i>Dendrimer-based synthetic vector for targeted cancer gene therapy</i> .....	214
Devices for nanotechnology-based cancer therapy .....	214
<i>Convection-enhanced delivery with nanoliposomal CPT-11</i> .....	214
<i>Nanocomposite devices</i> .....	214
<i>Nanoengineered silicon for brachytherapy</i> .....	215
<i>Nanosensors for targeted drug delivery in cancer</i> .....	215
Nanoparticles combined with physical agents for tumor ablation .....	215
<i>Carbon nanotubes for laser-induced cancer destruction</i> .....	215
<i>Nanoparticles and thermal ablation</i> .....	216
<i>Nanoparticles combined with ultrasound radiation of tumors</i> .....	218
<i>Nanoparticles as adjuncts to photodynamic therapy of cancer</i> .....	218
<i>Nanoparticles for boron neutron capture therapy</i> .....	219
RNA nanotechnology for delivery of cancer therapeutics .....	219
Nanocarriers for simultaneous delivery of multiple anticancer agents.....	220
Combination delivery systems for nanoparticle penetration into tumor tissue .....	220
Combination of diagnostics and therapeutics for cancer .....	221
<i>Biomimetic nanoparticles targeted to tumors</i> .....	221
<i>Dendrimer nanoparticles for targeting and imaging tumors</i> .....	221
<i>Gold nanoparticle plus bombesin for imaging and therapy of cancer</i> .....	221
<i>Gold nanorods for diagnosis plus photothermal therapy of cancer</i> .....	221
<i>Magnetic nanoparticles for imaging as well as therapy of cancer</i> .....	222
<i>Nanobialys for combining MRI with delivery of anticancer agents</i> .....	222
<i>Nanorobotics for detection and targeted therapy of cancer</i> .....	223
<i>pHLIP nanotechnology for detection and targeted therapy of cancer</i> .....	223
<i>Polymer nanobubbles for targeted and controlled drug delivery</i> .....	224
<i>Radiolabeled carbon nanotubes for tumor imaging and targeting</i> .....	224
<i>Targeted therapy with magnetic nanomaterials guided by antibodies</i> .....	224
<i>Ultrasonic tumor imaging and targeted chemotherapy by nanobubbles</i> .....	225
<i>Future of nanobiotechnology and targeted cancer therapy</i> .....	225
<b>Polyethylene glycol technology</b> .....	<b>225</b>
Enzon's PEG technology .....	226
Debiopharm's PEG biconjugate drug delivery platform .....	226
Nektar PEGylation .....	227
PEG Intron .....	227
<b>Single-chain antibody-binding protein technology</b> .....	<b>227</b>
<b>Vesicular systems for drug delivery in cancer</b> .....	<b>228</b>
<b>Liposomes for anticancer drug delivery</b> .....	<b>228</b>
Antibody-targeted liposomes for cancer therapy .....	229
ALZA's Stealth liposomes .....	229
Boron-containing liposomes .....	229
DepoFoam technology .....	230
Hyperthermia and liposomal drug delivery .....	230
Liposomal doxorubicin formulation with N-octanoyl-glucosylceramide .....	230
Liposome-nucleic acid complexes for anticancer drug delivery .....	231
Non-polygylated liposomal doxorubicin .....	231
Tumor-selective targeted drug delivery via folate-PEG liposomes .....	231
Ultrasound-mediated anticancer drug release from liposomes.....	231
Companies developing liposome-based anticancer drugs.....	232
<b>Pharmacosomes for controlled anticancer drug delivery</b> .....	<b>233</b>
<b>Emulsion formulations of anticancer drugs</b> .....	<b>233</b>
<b>Albumin-based drug carriers</b> .....	<b>234</b>
<b>Anticancer drugs that bind to tumors</b> .....	<b>234</b>
<b>Monoclonal T cell receptor technology</b> .....	<b>234</b>
<b>Radioactive materials for diagnosis and targeted radiotherapy</b> .....	<b>235</b>
Intraperitoneal vs intravenous radioimmunotherapy .....	235
Peptide receptor radionuclide therapy.....	236
Pretargeted radioimmunotherapy of cancer .....	236
Radiolabeled somatostatin receptor antagonists.....	236
Theophylline enhances radioiodide uptake by cancer .....	237
<b>Strategies for drug delivery in cancer</b> .....	<b>237</b>
Direct introduction of anticancer drugs into the tumor .....	238
<i>Injection into the tumor</i> .....	238
<i>Antineoplastic drug implants into tumors</i> .....	239
<i>Tumor necrosis therapy</i> .....	239
<i>Injection into the arterial blood supply of cancer</i> .....	240
<i>Electrochemotherapy</i> .....	241
<i>Pressure-induced filtration of drugs across vessels to the tumor</i> .....	242
Improving drug transport to tumors .....	242
<i>Carbohydrate-enhanced chemotherapy</i> .....	242
<i>Dextrans as macromolecular anticancer drug carriers</i> .....	242
<i>In situ production of anticancer agents in tumors</i> .....	243

<i>Iotophoresis for localized delivery of cancer chemotherapy .....</i>	243
Strategies for increasing drug penetration into solid cancers .....	243
Selective destruction of cancer cells .....	244
<i>Hyperbaric oxygen .....</i>	244
<i>Sphingolipids.....</i>	244
<i>Targeting response to transformation-induced oxidative stress .....</i>	245
<i>Targeting enzymes to prevent proliferation of cancer cells.....</i>	245
Targeted drug delivery in cancer .....	245
<i>Affibody molecules for targeted anticancer therapy .....</i>	247
<i>Fatty acids as targeting vectors .....</i>	247
<i>Genetic targeting of the kinase activity in cancer cells .....</i>	248
<i>Heat-activated targeted drug delivery.....</i>	248
<i>Novel transporters to target photosensitizers to cancer cell nuclei.....</i>	249
<i>Photodynamic therapy of cancer .....</i>	249
<i>Radionuclides delivered with receptor targeting technology .....</i>	250
<i>Targeting ligands specific for cancer cells .....</i>	250
<i>Targeting abnormal DNA in cancer cells .....</i>	250
<i>Targeted delivery by tumor-activated prodrug therapy .....</i>	250
<i>Targeting glutathione S-transferase .....</i>	252
<i>Targeting tumors by exploiting leaky blood vessels .....</i>	253
<i>Targeted drug delivery of anticancer agents with controlled activation .....</i>	253
<i>Targeted delivery of anticancer agents with ReCODE™ technology .....</i>	253
<i>Transmembrane Carrier Systems .....</i>	254
<i>Transferrin-oligomers as targeting carriers in anticancer drug delivery.....</i>	254
<i>Tumor targeting with peptides .....</i>	254
<i>Tumor-targeted delivery of immune checkpoint inhibitors .....</i>	255
<i>Ultrasound and microbubbles for targeted anticancer drug delivery .....</i>	255
<i>Ultrasound for targeted delivery of chemotherapeutics .....</i>	256
<i>Vitamin B12 and folate for targeting cancer chemotherapy.....</i>	256
Cell-based drug delivery in cancer.....	257
<i>Red blood cells as vehicles for drug delivery .....</i>	258
<i>Cells as vehicles for gene delivery .....</i>	258
Drug delivery in relation to circadian rhythms.....	258
Implants for systemic delivery of anticancer drugs .....	259
<i>Drug-eluting polymer implants .....</i>	260
Angiogenesis and drug delivery to tumors .....	260
Antiangiogenesis strategies .....	261
<i>Targeting tumor endothelial cells .....</i>	261
<i>Methods for overcoming limitations of antiangiogenesis approaches .....</i>	261
Vascular targeting agents .....	262
<i>Alpha-emitting antibodies for vascular targeting .....</i>	262
<i>Angiolytic therapy.....</i>	263
<i>Anti-phosphatidylserine antibodies as VTA .....</i>	263
<i>Vadimezan .....</i>	264
<i>Cadherin inhibitors .....</i>	264
<i>Fosbretabulin tromethamine.....</i>	264
<i>Drugs to induce clotting in tumor vessels .....</i>	265
<i>Selective permeation of the anticancer agent into the tumor .....</i>	265
<i>Targeted delivery of tissue factor .....</i>	266
<i>Vascular targeting agents versus antiangiogenesis agents .....</i>	266
<i>ZD6126 .....</i>	266
Delivery of proteins and peptides for cancer therapy .....	267
<i>CELLECTRA™ electroporation device.....</i>	268
<i>Emisphere's Eligen™ system .....</i>	268
<i>Diatos Peptide Vector intra-cellular/intra-nuclear delivery technology .....</i>	268
<i>Lytic peptides and cancer.....</i>	269
<i>Modification of proteins and peptides with polymers .....</i>	269
<i>Peptide-based targeting of cancer biomarkers for drug delivery .....</i>	269
<i>Peptide-cytokine complexes as vascular targeting agents.....</i>	270
<i>Peptide-polymer conjugates with radionuclides .....</i>	270
<i>Transduction of proteins in vivo .....</i>	271
<i>Tumor targeting by stable toxin (ST) peptides .....</i>	271
Image-guided personalized drug delivery in cancer .....	271
A computational approach to integration of drug delivery methods for cancer.....	271
<b>4. Delivery of Biological Therapies for Cancer.....</b>	<b>274</b>
<b>Introduction .....</b>	<b>274</b>
<b>Antisense therapy.....</b>	<b>274</b>
<i>Basics of antisense approaches.....</i>	274
<i>Antisense cancer therapy .....</i>	274
<i>Mechanisms of anticancer effect of antisense oligonucleotides .....</i>	275

Selected antisense drugs in development for cancer .....	275
<i>Antisense targeted to ribonucleotide reductase</i> .....	275
<i>Immune modulatory oligonucleotide</i> .....	276
Ribozyme therapy .....	276
Spiegelmers .....	277
Antisense drug delivery issues .....	277
Strategies to overcome delivery problems of antisense oligonucleotides .....	278
<i>Antisense delivery in microspheres</i> .....	278
<i>Delivery of antisense using nanoparticles</i> .....	278
<i>Delivery across the blood-brain barrier</i> .....	279
<i>Delivery of ribozymes</i> .....	279
<i>Iontophoretic delivery of oligonucleotides</i> .....	279
<i>Liposomes-mediated oligonucleotide delivery</i> .....	280
<i>Neugene™ antisense drugs</i> .....	280
<i>Oral delivery of oligonucleotides</i> .....	280
<i>Peptide nucleic acid delivery</i> .....	281
<i>Receptor-mediated endocytosis</i> .....	281
<i>Delivery of ribozymes</i> .....	281
Combination of antisense and electrochemotherapy .....	282
Aptamers for combined diagnosis and therapeutics of cancer .....	282
Antisense compounds in clinical trials .....	283
<b>RNA interference .....</b>	<b>283</b>
Basics of RNAi .....	283
Comparison of antisense and RNAi .....	283
RNAi applications in oncology .....	284
siRNA-based cancer immunotherapy .....	285
Delivery of siRNA in cancer .....	286
<i>Delivery of siRNA by nanoparticles</i> .....	286
<i>Delivery of siRNA by nanosize liposomes</i> .....	286
<i>Lipid nanoparticles for delivery of anticancer siRNAs</i> .....	287
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i> .....	288
Lipophilic siRNA for targeted delivery to solid tumors .....	289
Companies developing cancer therapies based on antisense and RNAi .....	289
<b>DNA interference .....</b>	<b>290</b>
<b>Cancer gene therapy .....</b>	<b>290</b>
Basics of gene therapy .....	290
Strategies for cancer gene therapy .....	291
Gene transfer techniques as applied to cancer gene therapy .....	292
<i>Viral vectors</i> .....	292
<i>Nonviral vectors</i> .....	293
<i>A polymer approach to gene therapy for cancer</i> .....	293
Direct gene delivery to the tumor .....	294
<i>Injection into tumor</i> .....	294
<i>Reversible electroporation</i> .....	295
Hematopoietic gene transfer .....	296
<i>Genetic modification of human hematopoietic stem cells</i> .....	296
Gene-based strategies for immunotherapy of cancer (immunogene therapy) .....	297
<i>Cytokine gene therapy</i> .....	297
Monoclonal antibody gene transfer .....	300
Transfer and expression of intracellular adhesion-1 molecules .....	301
Other gene therapy techniques for immunotherapy of cancer .....	301
<i>Chemokines</i> .....	301
<i>Engineered viruses as anticancer immunotherapy vectors</i> .....	301
<i>Fas (Apo-1)</i> .....	302
<i>IGF (Insulin-Like Growth Factor)</i> .....	302
<i>Major Histocompatibility Complex (MHC) Class I</i> .....	302
Inhibition of immunosuppressive function .....	302
microRNA gene therapy .....	303
Delivery of toxic genes to tumor cells for eradication (molecular chemotherapy) .....	303
<i>Gene-directed enzyme prodrug therapy</i> .....	303
Combination of gene therapy with radiotherapy .....	304
Multipronged therapy of cancer with microencapsulated cells .....	304
Correction of genetic defects in cancer cells (mutation compensation) .....	305
Targeted gene therapy for cancer .....	305
<i>Transcriptional targeting for cancer gene therapy</i> .....	305
<i>Targeted epidermal growth factor-mediated DNA delivery</i> .....	306
<i>Gene-based targeted drug delivery to tumors</i> .....	306
<i>Targeting gene expression to hypoxic tumor cells</i> .....	307
<i>Targeting gene expression by progression-elevated gene-3 promoter</i> .....	307
<i>Targeted delivery of retroviral particles hitchhiking on T cells</i> .....	307
<i>Targeting tumors with genetically modified T cells</i> .....	308

<i>Targeting tumors by genetically engineered stem cells .....</i>	308
<i>Tumor-targeted gene therapy by receptor-mediated endocytosis .....</i>	309
<i>Targeted site-specific delivery of anticancer genes by nanoparticles .....</i>	309
<i>Immunolipoplex for delivery of p53 gene .....</i>	309
<i>Combination of electrogene and electrochemotherapy .....</i>	310
<b>Virus-mediated oncolysis .....</b>	<b>310</b>
<i>Targeted cancer treatments based on oncolytic viruses.....</i>	310
<i>Oncolytic gene therapy .....</i>	311
<i>Cancer terminator virus .....</i>	311
<i>Cytokine-induced killer cells for delivery of an oncolytic virus .....</i>	312
<i>Facilitating oncolysis by targeting innate antiviral response by HDIs .....</i>	312
<i>Oncolytic HSV.....</i>	312
<i>Oncolytic adenoviruses .....</i>	313
<i>Oncolytic Coxsackie virus A21 .....</i>	315
<i>Oncolytic vesicular stomatitis virus.....</i>	315
<i>Oncolytic measles virus .....</i>	315
<i>Oncolytic paramyxovirus.....</i>	316
<i>Oncolytic reovirus .....</i>	316
<i>Oncolytic vaccinia virus.....</i>	317
<i>Synthetic oncolytic virus .....</i>	317
<i>Monitoring of viral-mediated oncolysis by PET.....</i>	317
<i>Companies developing oncolytic viruses.....</i>	318
<b>Antiangiogenic therapy for cancer .....</b>	<b>318</b>
<b>Apoptotic approach to improve cancer gene therapy.....</b>	<b>319</b>
<b>Bacteria as novel anticancer gene vectors .....</b>	<b>320</b>
<b>Concluding remarks on cancer gene therapy .....</b>	<b>320</b>
<b>Cancer gene therapy companies .....</b>	<b>321</b>
<b>Cell therapy for cancer.....</b>	<b>323</b>
<i>Cellular immunotherapy for cancer.....</i>	324
<i>Treatments for cancer by ex vivo mobilization of immune cells .....</i>	324
<i>Granulocytes as anticancer agents .....</i>	325
<i>Neutrophil granulocytes in antibody-based immunotherapy of cancer .....</i>	325
<i>Use of hematopoietic stem cells for targeted cancer therapy .....</i>	325
<b>Cancer vaccines .....</b>	<b>326</b>
<i>Cell-based cancer vaccines.....</i>	326
<i>Autologous tumor cell vaccines .....</i>	326
<i>Vaccines that simultaneously target different cancer antigens.....</i>	327
<i>Delivery systems for cell-based cancer vaccines.....</i>	327
<i>Intra-lymph node injections of cancer vaccine antigens .....</i>	328
<i>Nucleic acid-based cancer vaccines .....</i>	328
<i>Antiangiogenic DNA cancer vaccine .....</i>	328
<i>DNA cancer vaccines .....</i>	328
<i>Methods of delivery of DNA vaccines .....</i>	329
<i>RNA vaccines.....</i>	330
<i>Viral vector-based cancer vaccines .....</i>	330
<i>Companies involved in nucleic acid-based vaccines .....</i>	331
<i>Genetically modified cancer cells vaccines .....</i>	332
<i>GVAX cancer vaccines .....</i>	332
<i>Genetically modified dendritic cells.....</i>	333
<i>Multipeptide-based cancer vaccines .....</i>	333
<b>5. Delivery strategies according to cancer type and location .....</b>	<b>334</b>
<b>Introduction .....</b>	<b>334</b>
<b>Bladder cancer .....</b>	<b>334</b>
<i>Intravesical drug delivery.....</i>	334
<i>Intravesical agents combined with systemic chemotherapy .....</i>	334
<i>Targeted anticancer therapy for bladder cancer .....</i>	335
<i>Prodrug EOquin for bladder cancer .....</i>	335
<i>Antisense treatment of bladder cancer.....</i>	336
<i>Gene therapy for bladder cancer .....</i>	336
<b>Brain tumors .....</b>	<b>336</b>
<i>Methods for evaluation of anticancer drug penetration into brain tumor .....</i>	337
<i>Innovative methods of drug delivery for glioblastoma .....</i>	337
<i>Delivery of anticancer drugs across the blood-brain barrier .....</i>	338
<i>Anticancer agents with increased penetration of BBB.....</i>	338
<i>BBB disruption.....</i>	339
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB.....</i>	340
<i>Tyrosine kinase inhibitor increases topotecan penetration into CNS .....</i>	341
<i>Bypassing the BBB by alternative methods of drug delivery.....</i>	341
<i>Intranasal perillyl alcohol .....</i>	341
<i>Intraarterial chemotherapy .....</i>	341

Enhancing tumor permeability to chemotherapy .....	342
Local delivery of chemotherapeutic agents into the tumor .....	343
<i>Carmustine biodegradable polymer implants</i> .....	343
<i>Fibrin glue implants containing anticancer drugs</i> .....	343
<i>Biodegradable microspheres containing 5-FU</i> .....	344
<i>Magnetically controlled microspheres</i> .....	344
Convection-enhanced delivery .....	344
<i>CED for receptor-directed cytotoxin therapy</i> .....	344
<i>CED of topotecan</i> .....	345
<i>CED of a modified diphtheria toxin conjugated to transferrin</i> .....	345
<i>CED of nanoliposomal CPT-11</i> .....	345
<i>CED for delivery <math>^{131}I</math>-chTNT-1/B MAb</i> .....	346
Anticancer drug formulations for targeted delivery to brain tumors .....	346
<i>Intravenous delivery of anticancer agents bearing transferrin</i> .....	346
<i>Liposomes for drug delivery to brain tumors</i> .....	346
<i>MAbs targeted to brain tumors</i> .....	347
<i>Multiple targeted drugs for brain tumors</i> .....	347
<i>Nanoparticles for targeted drug delivery in glioblastoma</i> .....	348
<i>Aurora kinase B siRNA &amp; lactoferrin nanoparticles with temozolamide</i> .....	349
<i>Targeted antiangiogenic/apoptotic/cytotoxic therapies</i> .....	349
<i>Targeted drug delivery to gliomas using cholera toxin subunit B</i> .....	350
Introduction of the chemotherapeutic agent into the CSF pathways.....	350
<i>Intraventricular chemotherapy for meningeal cancer</i> .....	350
<i>Intrathecal chemotherapy</i> .....	351
Interstitial delivery of dexamethasone for reduction of peritumor edema .....	351
Combination of chemotherapy with radiotherapy .....	352
Photodynamic therapy for chemosensitization of brain tumors .....	352
<i>Nanoparticles for photodynamic therapy of brain tumors</i> .....	352
Innovative delivery of radiotherapy to brain tumors .....	353
<i>GliaSite Radiation Therapy System</i> .....	353
<i>Boron neutron capture therapy for brain tumors</i> .....	353
Cell therapy for glioblastoma .....	354
<i>Chimeric antigen receptor T cells</i> .....	354
<i>Mesenchymal stem cells to deliver treatment for gliomas</i> .....	354
<i>Stem cell-based therapy targeting EGFR in glioblastoma</i> .....	354
Gene therapy for glioblastoma .....	354
<i>Antiangiogenic gene therapy</i> .....	356
<i>Anticancer drug delivery by genetically engineered MSCs</i> .....	356
<i>Gene transfer to brain tumor across the BBB by nanobiotechnology</i> .....	356
<i>Intracerebroventricular delivery of gene therapy for gliomas by NSCs</i> .....	356
<i>Intravenous gene delivery with nanoparticles into brain tumors</i> .....	357
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i> .....	357
<i>MSC-based gene delivery to glioblastoma</i> .....	358
<i>Neural stem cells for drug/gene delivery to brain tumors</i> .....	358
<i>Peptides targeted to glial tumor cells</i> .....	359
<i>RNAi gene therapy of brain cancer</i> .....	359
<i>Single-chain antibody-targeted adenoviral vectors</i> .....	360
<i>Targeting normal brain cells with an AAV vector encoding interferon-<math>\beta</math></i> .....	360
<i>Treatment of medulloblastoma by suppressing genes in Shh pathway</i> .....	360
Virus-mediated oncolytic therapy of glioblastoma.....	361
<i>Clinical trials of viral oncolysis of glioblastoma</i> .....	362
<i>Oncolytic viral delivery by stem cells for brain metastases</i> .....	363
<i>Future of viral-mediated oncolysis</i> .....	364
Vaccination for glioblastoma.....	364
<i>Cell-based vaccines for glioblastoma</i> .....	364
<i>Peptide vaccines for glioblastoma</i> .....	364
<i>Poliovirus-based vaccine for glioblastoma</i> .....	365
<b>Breast Cancer .....</b>	<b>366</b>
Therapies for breast cancer involving innovative methods of drug delivery .....	367
Injectable biodegradable polymer delivery system for local chemotherapy .....	367
MammoSite brachytherapy.....	367
Monoclonal antibodies targeted to HER2 receptor .....	368
Breast cancer vaccines .....	368
<i>HER-2 DNA AutoVac™ vaccine</i> .....	369
<i>Recombinant adenoviral ErbB-2/neu vaccine</i> .....	369
<i>Gene vaccine for breast cancer</i> .....	370
<i>NeuVax</i> .....	370
Gene therapy for breast cancer.....	371
Antisense therapy for breast cancer .....	371
Inhibitors of growth factors FGF2 and VEGF for breast cancer .....	372
Targeted multi-drug delivery approach to breast cancer.....	372

<b>Cancer of the cervix and the uterus .....</b>	<b>372</b>
Gene therapy for cervical cancer.....	372
Delivery of chemoradiation therapy .....	372
Cervical cancer vaccines .....	373
<b>Cancer of the liver .....</b>	<b>373</b>
Hepatocellular carcinoma .....	373
Treatment of liver metastases .....	374
<b>Gastrointestinal cancer.....</b>	<b>375</b>
Colorectal cancer .....	375
<i>Oxaliplatin long-circuting liposomes</i> .....	375
<i>Perifosine</i> .....	375
<i>Targeted delivery of triple anticancer therapy by local patch</i> .....	376
Gastrointestinal stromal tumor .....	376
Vaccines for gastrointestinal cancer.....	376
<b>Hematological malignancies .....</b>	<b>376</b>
Leukemia.....	376
<i>Clofarabine</i> .....	377
<i>Ibrutinib</i> .....	378
<i>Idelalisib for CLL</i> .....	378
Multiple myeloma.....	378
<i>Monoclonal antibody therapy in multiple myeloma</i> .....	378
Non-Hodgkin's lymphoma .....	379
<i>Idelalisib for NHL</i> .....	379
<i>Pixantrone</i> .....	379
<i>Rituximab after autologous stem-cell transplantation</i> .....	379
<b>Malignant melanoma .....</b>	<b>380</b>
Targeted therapies for melanoma .....	380
Immunotherapy for malignant melanoma .....	381
Gene therapy for malignant melanoma .....	381
<b>Nasopharangeal carcinoma.....</b>	<b>383</b>
Synergistic effect of gene therapy with 5-FU .....	383
<b>Neuroblastoma .....</b>	<b>384</b>
Genetically modified NSCs for treatment of neuroblastoma .....	384
<b>Non-small cell lung cancer.....</b>	<b>384</b>
Aerosol delivery of anticancer agents for lung cancer.....	385
Aerosol gene delivery for lung cancer .....	386
Complex nanoscale pulmonary delivery of drugs for resistant lung cancer .....	386
Intratumoral administration of anticancer drugs through a bronchoscope.....	387
<b>Ovarian cancer.....</b>	<b>387</b>
Dendritic cell vaccination for ovarian cancer .....	387
Gene Therapy for ovarian cancer .....	387
Innovative drug delivery for ovarian cancer.....	388
Intravenous ascorbate for ovarian cancer.....	389
Intraperitoneal delivery .....	389
Intraperitoneal hyperthermic chemotherapy in ovarian cancer .....	390
Modulation of protein ubiquitination .....	390
Targeting Notch pathway to overcome resistance to chemotherapy .....	390
<b>Pancreatic cancer .....</b>	<b>391</b>
Delivery of chemotherapy for pancreatic cancer .....	391
<i>Local drug delivery</i> .....	391
<i>Localized drug delivery by iontophoresis</i> .....	391
<i>Nanoparticle-based delivery of tumor-penetrating peptides</i> .....	392
<i>Targeted chemotherapy for pancreatic cancer</i> .....	392
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i> .....	392
Vaccine for pancreatic cancer .....	393
Gene therapy for pancreatic cancer .....	393
<i>Correction of altered genes</i> .....	393
<i>Targeted gene therapy</i> .....	394
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i> .....	394
<i>Targeted Expression of BikDD gene</i> .....	394
<i>Viral oncolysis in pancreatic cancer</i> .....	394
<b>Prostate cancer.....</b>	<b>395</b>
Alpha emitter radium-223 for targeting bone metastases in cancer .....	396
Brachytherapy for cancer of prostate.....	396
<i>Brachytherapy via paravertebral approach lymph node metastases</i> .....	396
Capridine-beta.....	396
LHRH for prostate cancer .....	397
<i>LHRH analogs</i> .....	397
<i>Histrelin implant</i> .....	397
Immunomodulatory drugs.....	397
MAbs for prostate cancer .....	397

PACLIMER Microspheres.....	398
PRX302 .....	398
Targeted therapies for prostate cancer .....	399
<i>Delivery of cisplatin to prostate cancer by nanoparticles .....</i>	399
<i>Delivery of siRNAs to prostate cancer with aptamer-siRNA chimeras.....</i>	399
<i>Delivery of siRNA for prostate cancer with metastases.....</i>	399
<i>Gold nanoparticles targeted to laminin receptor in prostate cancer.....</i>	399
<i>PSA-activated protoxin that kills prostate cancer.....</i>	400
<i>Targeted delivery of a nanoparticulate platinum prodrug.....</i>	400
<i>Targeting oncogene MDM2 in prostate cancer.....</i>	400
<i>Vascular targeting of prostate cancer .....</i>	401
Gene therapy for cancer of prostate .....	401
<i>Experimental studies .....</i>	401
<i>Nanoparticule-based gene therapy for prostate cancer.....</i>	401
<i>Tumor suppressor gene therapy in prostate cancer .....</i>	402
<i>Vaccines for prostate cancer.....</i>	402
<i>Clinical trials of gene therapy for prostate cancer .....</i>	403
Viral oncolysis for prostate cancer.....	404
Combined approaches .....	404
Combined autovaccination and hyperthermia .....	404
<b>Thyroid cancer .....</b>	<b>405</b>
<b>6. Cancer drug delivery markets .....</b>	<b>406</b>
<b>Introduction .....</b>	<b>406</b>
Global markets for drug delivery .....	406
Estimation of cancer drug delivery markets .....	406
<i>Methods used for market estimation.....</i>	406
<i>Cancer epidemiology .....</i>	407
<i>Cost of patient care in cancer .....</i>	408
<b>Market forecasts 2019-2029 .....</b>	<b>409</b>
Cancer drug market .....	409
<i>Market for leukemia .....</i>	410
<i>Market for lymphoma .....</i>	410
<i>Markets for brain tumors .....</i>	410
<i>Market for breast cancer.....</i>	411
<i>Market for ovarian cancer .....</i>	411
<b>Geographical distribution of cancer markets .....</b>	<b>411</b>
Factors affecting future cancer markets .....	411
<b>Market share according to cancer drug delivery technologies.....</b>	<b>412</b>
Antiangiogenesis therapies.....	412
Antibody drug conjugates .....	413
Antineoplastic drug implants for systemic administration .....	413
Antisense therapy and RNAi .....	413
Cancer vaccines.....	413
Cell/gene therapy .....	414
Liposomes for anticancer drugs .....	414
Monoclonal antibodies .....	414
Modulators of protein ubiquitination .....	415
<b>Strategic aspects of cancer drug delivery .....</b>	<b>415</b>
<b>Unmet needs in cancer drug delivery.....</b>	<b>415</b>
<b>Future of cancer drug delivery.....</b>	<b>416</b>
Cancer drug delivery and pharmacogenomics .....	416
Cancer immunotherapy markets .....	417
Drug delivery for cancer in the postgenomic era .....	417
Role of nanobiotechnology in development of cancer drug delivery markets .....	417
Expansion of cancer drug delivery markets in developing countries .....	417
Drivers for the development of drug delivery technologies in cancer .....	417
<b>7. References.....</b>	<b>420</b>

## Tables

Table 1-1: Estimated new cases of cancer in the US at most involved organs – 2017 .....	52
Table 1-2: Historical landmarks in drug delivery for cancer .....	55
Table 2-1: Innovative strategies against cancer.....	58
Table 2-2: A classification of antiangiogenic therapies .....	61
Table 2-3: Selected antiangiogenic agents in development for cancer.....	67
Table 2-4: Approaches to cancer therapy based on bacteria .....	69
Table 2-5: Cell therapy technologies used for cancer .....	77

Table 2-6: Non-nucleic acid cancer vaccines without genetic modification .....	81
Table 2-7: Monoclonal antibodies for cancer approved by the FDA .....	93
Table 2-8: Anticancer agents linked to monoclonal antibodies .....	98
Table 2-9: Monoclonal antibodies in clinical trials for cancer .....	101
Table 2-10: Antibody drug conjugates in clinical trials for cancer .....	109
Table 2-11: Third generation boron delivery agents currently under investigation .....	113
Table 2-12: Cellular pathways as targets for anticancer therapies .....	120
Table 2-13: Examples of anticancer agents that target mitochondrial membranes .....	122
Table 2-14: Drugs targeting oncogenes .....	126
Table 2-15: PARP inhibitors for cancer therapy .....	148
Table 2-16: Cancer therapies based on the P53 .....	153
Table 2-17: Promise of personalized therapy in cancer .....	157
Table 2-18: Companies developing personalized therapy for cancer .....	158
Table 3-1: Routes of drug delivery in cancer .....	165
Table 3-2: Systemic intravenous drug delivery systems for chemotherapy of cancer .....	165
Table 3-3: Approved oral chemotherapy drugs .....	167
Table 3-4: Microparticles as therapeutic delivery systems in cancer .....	181
Table 3-5: Classification of nanobiotechnology approaches to drug delivery in cancer .....	185
Table 3-6: Approved anticancer drugs using nanocarriers .....	186
Table 3-7: Clinical trials of anticancer drugs using nanocarriers .....	186
Table 3-8: Marketed preparations for liposome-based anticancer drugs .....	232
Table 3-9: Clinical trials of liposome-based anticancer drugs .....	232
Table 3-10: Strategies for drug delivery in cancer .....	237
Table 3-11: Implant systems for delivery of anticancer drugs into tumors .....	239
Table 3-12: Targeted delivery of anticancer therapeutics .....	246
Table 3-13: Methods of delivery of antiangiogenesis therapies .....	261
Table 3-14: Companies developing vascular targeting agents .....	262
Table 4-1: Mechanisms of anticancer effect of antisense oligonucleotides .....	275
Table 4-2: Methods of delivery of oligonucleotides for cancer therapy .....	277
Table 4-3: Antisense oligonucleotides in clinical trials for cancer .....	283
Table 4-4: Companies developing antisense and RNAi therapies for cancer .....	289
Table 4-5: Strategies for cancer gene therapy .....	291
Table 4-6: Enzyme/prodrug combinations employed in suicide gene therapy .....	303
Table 4-7: Mutation compensation strategies used clinically .....	305
Table 4-8: Companies developing oncolytic viruses .....	318
Table 4-9: Companies involved in cancer gene therapy .....	321
Table 4-10: Cell therapy technologies used for cancer .....	323
Table 4-11: Companies developing nucleic acids/genetically modified cells-based cancer vaccines .....	331
Table 5-1: Innovative methods of drug delivery for glioblastoma .....	337
Table 5-2: Strategies for gene therapy of malignant brain tumors .....	355
Table 5-3: Clinical trials of virotherapies for glioblastoma .....	363
Table 5-4: Therapies for breast cancer involving innovative methods of drug delivery .....	367
Table 5-5: Drug delivery for hepatocellular carcinoma .....	373
Table 5-6: Gene therapy for malignant melanoma .....	382
Table 5-7: Targeted treatment of non-small cell lung cancer .....	385
Table 5-8: Clinical trials of gene therapy in ovarian cancer .....	388
Table 5-9: Methods of drug delivery in pancreatic cancer .....	391
Table 5-10: Pharmacological strategies under investigation for cancer of the prostate .....	395
Table 5-11: Clinical trials of gene therapy for prostate cancer .....	403
Table 6-1: Worldwide drug delivery market growth 2019 to 2029 .....	406
Table 6-2: Worldwide prevalence of cancer according to type of cancer 2019-2029 .....	407
Table 6-3: Estimated number of cancer patients in major markets 2019-2029 .....	408
Table 6-4: Worldwide anticancer drug sales for from 2019 to 2029 .....	410
Table 6-5: Geographical distribution of cancer markets 2019-2029 .....	411
Table 6-6: Market values of cancer drug delivery technologies from 2019-2029 .....	412

## Figures

Figure 1-1: Structure of PD-1 pathway .....	26
Figure 1-2: Signaling pathway changes during adaptation of cancer cell to hypoxia .....	35
Figure 1-3: Nitric oxide: tumor enhancement or inhibition .....	38
Figure 1-4: Role of nitric oxide in angiogenesis .....	41
Figure 1-5: An overview of some key steps in tumor angiogenesis .....	47
Figure 2-1: Targeting tumors with light-emitting engineered bacteria .....	71
Figure 2-2: Enhancing tumor-cell visibility to the immune system by viral mimicry .....	80
Figure 2-3: Schematic role of T helper cells in immune response to cancer .....	85
Figure 2-4: G-MAB™ technology .....	106
Figure 2-5: Antimetabolic anticancer effect of SR9243 by inhibiting Warburg effect .....	152
Figure 3-1: Cyclacel's Penetratin Transport System for delivery of drugs to targets .....	177
Figure 3-2: Linker Activated Drug Release .....	179

Figure 3-3: Micelle for drug delivery in cancer .....	191
Figure 3-4: Targeted drug delivery with QA-NPs via peritumoral blood vessels .....	210
Figure 3-5: Mechanism of action of Targaceutical drugs.....	247
Figure 3-6: VIADUR leuprolide acetate using Duros implant technology .....	259
Figure 4-1: Mechanism of action of oncolytic viruses .....	310
Figure 5-1: A concept of targeted drug delivery to GBM across the BBB.....	340
Figure 5-2:Mechanism of antitumor effects of poliovirus-based vaccine for glioblastoma.....	366
Figure 6-1: Unmet needs in cancer drug delivery .....	416